Complete endosonographic staging of lung cancer: a systematic single scope approach.
Completed
- Conditions
- lung cancer10029107
- Registration Number
- NL-OMON39836
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 150
Inclusion Criteria
lung cancer
indication for mediastinal staging
resectable lung tumor
patient is operable
Exclusion Criteria
distant metastases of lung cancer
mediastinal lymph nodes not within reach of EBUS
former lung cancer treatment
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The main study parameter is the sensitivity for loco regional disease ( N2, N3,<br /><br>T4 disease) of complete endosonographic staging (by EBUS-TBNA and EUS-B-FNA) in<br /><br>comparison to EBUS staging alone.</p><br>
- Secondary Outcome Measures
Name Time Method <p>1. Sensitivity for locally advanced disease (N2-3 metastases, T4) of systematic<br /><br>assessment and sampling of mediastinal lymph nodes in comparison to PET-CT<br /><br>directed assessment of the mediastinum (ie targeted approach).<br /><br>2. The assessment of the left adrenal gland by EUS-B is feasible.</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular subtypes of lung cancer benefit most from endosonographic staging using a single scope approach?
How does endosonographic staging with a single scope compare to traditional bronchoscopy in detecting mediastinal lymph node metastases?
Which biomarkers correlate with improved staging accuracy in endosonographic lung cancer trials like NL-OMON39836?
What are the long-term adverse event rates associated with systematic endosonographic staging in non-small cell lung cancer patients?
How does endosonographic staging influence treatment decisions for EGFR-mutated or ALK-positive lung cancer subpopulations?